SEC Form 4 · accession 0001455244-15-000025
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John W Kozarich
Director
Period of report
Jun 29, 2015
Accepted (ET)
Jul 1, 2015 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Jun 29, 2015 | M | 12,500 | $3.67 | A | 44,500 | D | |
| Common SharesF2 | Jun 29, 2015 | M | 12,500 | $3.30 | A | 57,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F3 | $3.67 | Jun 29, 2015 | M | 12,500 | D | — | Jul 15, 2023 | Common Shares | 12,500 | 0 | D |
| Stock Option (right to buy)F2,F4 | $3.30 | Jun 29, 2015 | M | 12,500 | D | — | Dec 17, 2024 | Common Shares | 12,500 | 0 | D |
Explanation of responses
- F1Price reflects the conversion of Canadian dollars to US dollars based on the exchange rate in effect as of the date of the reportable event. The option exercise price is CAD $4.54 per share, which was the closing price of the Issuer's common stock on the Toronto Stock Exchange as of the date of grant.
- F2Price reflects the conversion of Canadian dollars to US dollars based on the exchange rate in effect as of the date of the reportable event. The option exercise price is CAD $4.08 per share, which was the closing price of the Issuer's common stock on the Toronto Stock Exchange as of the date of grant.
- F3The options were scheduled to vest and become exercisable in thirty-six (36) successive and equal monthly installments beginning on the one-month anniversary of the date of grant (or August 15, 2013), such that 100% of the options would be fully vested on July 15, 2016. On June 7, 2015, the Board of Directors of QLT approved the immediate vesting of all stock options held by the Reporting Person.
- F4The options were scheduled to vest and become exercisable in thirty-six (36) successive and equal monthly installments beginning on the one-month anniversary of the date of grant (or January 17, 2015), such that 100% of the options would be fully vested on December 17, 2017. On June 7, 2015, the Board of Directors of QLT approved the immediate vesting of all stock options held by the Reporting Person.